D. Boral Capital Reiterates Buy Rating for Anixa Biosciences (NASDAQ:ANIX)

D. Boral Capital restated their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research note published on Wednesday,Benzinga reports. The brokerage currently has a $10.00 price target on the stock.

Other equities analysts also recently issued reports about the stock. Maxim Group started coverage on shares of Anixa Biosciences in a research note on Friday, March 21st. They set a “buy” rating and a $10.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research report on Tuesday.

Anixa Biosciences Stock Down 3.6 %

Shares of NASDAQ ANIX opened at $2.97 on Wednesday. Anixa Biosciences has a twelve month low of $2.07 and a twelve month high of $4.20. The firm has a market cap of $95.63 million, a PE ratio of -7.62 and a beta of 0.86. The business has a fifty day simple moving average of $2.97 and a two-hundred day simple moving average of $3.00.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). On average, research analysts expect that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insider Transactions at Anixa Biosciences

In related news, CEO Amit Kumar acquired 43,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was acquired at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the purchase, the chief executive officer now owns 559,925 shares of the company’s stock, valued at approximately $1,248,632.75. This represents a 8.32 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lewis H. Titterton, Jr. bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, January 17th. The stock was purchased at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the transaction, the director now owns 922,334 shares in the company, valued at $2,370,398.38. This trade represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 75,289 shares of company stock valued at $177,021. Corporate insiders own 25.30% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

A number of large investors have recently bought and sold shares of the company. Millennium Management LLC purchased a new stake in shares of Anixa Biosciences in the 4th quarter valued at $26,000. Virtu Financial LLC purchased a new stake in Anixa Biosciences in the third quarter valued at $34,000. Renaissance Technologies LLC grew its position in Anixa Biosciences by 36.5% during the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock worth $34,000 after purchasing an additional 3,900 shares during the period. Prosperity Wealth Management Inc. purchased a new position in shares of Anixa Biosciences during the 4th quarter valued at about $54,000. Finally, Jane Street Group LLC acquired a new position in shares of Anixa Biosciences in the 4th quarter valued at about $67,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.